The second approach used transgenic mouse models that are prone to develop B-cell lymphoma owing to a human c-MYC transgene either under the regulatory control of the Eμ immunoglobulin heavy chain or Λ light chain enhancer (Eμ-Myc and Λ-Myc mice) (47). The gene discussed is MYC; the disease is B-cell non-Hodgkin lymphoma.